 All right. Why don't we go ahead and get started? I'm Terry Minolio from the National Human Genome Research Institute. My eye and my co-chair, Neil Scheer, are delighted to welcome you to this meeting on research directions in genetically mediated Stevens-Johnson syndrome, Toxic Epidermal Necrolysis. I thought it might be nice to start off by introducing ourselves around the table. So I'm Terry Minolio. Neil Scheer from the... Oh, yes. Don't forget to push your button. I just did that so you would remember. Neil Scheer from the University of Toronto. Lois Laguna from the FDA. Carolyn Header from NHGRI. Wen Hong-Zong from Taiwan. Lauren Trepanier from the University of Wisconsin. Sun Hong from Taiwan. Emrika Yuli-Ulan-Neri from the University of Jersey, Jakarta, Indonesia. I'm Jay Huffnago from NIDDK. Steve Leder from Children's Mercy Hospital in Kansas City. Mike Pakenovsky from FDA. David Veenstra University of Washington in Seattle. Wilson Tentorati from Brahmatipi Hospital, Mahidong University, Bangkok, Thailand. Manipra Mohamed from University of Liverpool, UK. Mike Lee from Riken, Japan, and Academia Sinica in Taiwan. Cynthia Sung from the Singapore Health Sciences Authority and also Duke NUS. Maya Malkenhub from Freiburg University, Germany. Josh Denne, Vanderbilt University. Elizabeth Phillips, Vanderbilt University. Vimon Sobanke Sa-Wong from Thai FDA. Simone Beniro, FDA. Bob Davis, University of Tennessee. It's recommended Mahasri Mungkon, Department of Medical Science, Minister of Health, Thailand. Hi, I'm Steve Katz, Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases. I'm Eric Green, Director of the National Human Genome Research Institute. I also want to add my own welcome to all of you, especially those who traveled far to get here. It's great to have you. I also want to point out our institute's video crew is back there videotaping this. We're broadcasting live and we're also going to be video archiving this, which we're delighted to do because we think it's important to have people who can't get to Bethesda be able to either watch it live or watch it after the fact. It is going to be important though to make sure that people are using microphones at all times because without the microphone, the video is just not going to pick it up, which makes me wonder how we're going to go around the rest of the room. But maybe for the introductions, we won't have everybody jump to a microphone. But when we get into question and answer sessions, everybody needs to use a mic. Thanks. Great point, Eric. And unfortunately, I think we'll skip introductions from the side just because it would be a little too hard to pass a microphone. But welcome, everyone, and we are delighted to have you here. One of the really neat things about being at NIH is that we can basically propose a topic for a meeting, invite people from far-flung regions of the globe, and really have the world's experts convene here even on miserable weather days to be able to give us advice on research directions. So we very much appreciate all of you coming. I would note that this meeting is really a collaboration among multiple institutes and the Food and Drug Administration. These are the various institutes that are providing funding, and then, of course, our Institute, the Human Genome Research Institute. I'm sort of charged with addressing a couple of important questions, kind of, how did we get here? Why this topic at this time? And also, what are the goals of today? And then we are asking you specific questions. Where do we go from here? And that's really the purpose of this meeting, is to get the brightest people that we could find around a table to address that. And a little bit of how do we get there? We worry a little bit more about the how after we define the what, but at any rate. And then you may have some questions for us, so we'll get into a little bit of the housekeeping things like where are the bathrooms, and that sort of thing. So we'll get to that. How did we get here? So one of the, as I said, one of the nice things about being at NIH is you can call people to address lots of very interesting questions. And we have a series of meetings in genomic medicine, or using a person's individual genetic results in their clinical care. The sixth meeting that we held about a year and a couple of months ago, in January of 2014, was a meeting of global leaders, really sort of asking what's going on internationally that could inform our efforts to implement genomic medicine? How could we learn from individual models perhaps in smaller settings that were more efficient and flexible? So this, like all of our genomic medicine meetings, is video cast and archived, thanks to Alvaro and his colleagues. And so it's on our website. If you can't remember this particular number, which I could see would be a problem. If you just Google NHGRI Genomic Medicine, it should come up. And this is the group that met in collaboration with the Institute of Medicine of the National Academy of Sciences. We were fortunate in having representatives from 25 countries, including a number of countries that we don't as often have represented in our meetings. And we were just delighted to get this part of the world coming to talk with us. One of the models that was discussed was Stevens-Johnson. And particularly, our colleague Wasson described the high prevalence of the risk alleles, this particular risk allele, in these parts of Southeast Asia. And an innovative approach that they've used using just a simple card like a credit card, and I hope he'll describe this better than I'm doing here, that basically has a person's genomic results related to the risk of Stevens-Johnson on them. And you can see here that the, so I need this pointer. The patient's name, the outcome of the assay, the date, the interpretation, and this particular person is at high risk. And then on the back of the card, further information that this person has this risk allele, and if you need more information, here's who you can contact. This was something that seemed so simple and so really, truly effective that it really caught the attention of the various groups in the meeting. And the idea was then, is this something that one could generalize, or at least try to spread beyond Thailand and potentially into broader parts of Southeast Asia, which I understand has been going on in other parts of the world, in other ways, and potentially even more broadly around the world. When we came back from that meeting, we then sort of looked at what NIH is doing in this area, and it turns out that we have almost zero portfolio in this condition, so maybe two or three grants at the most that we're funding, and that's out of the thousands and thousands that NIH funds. So we agreed among a group of institutes, since this does touch on multiple institutes and mandates, to pull together a meeting, this meeting, to review the current state of knowledge in surveillance pathogenesis and treatment, look at the role of genomics and pharmacogenomics in etiology treatment and eradication, and then identify gaps on met needs and priorities. And that's the work part of your day-to-day, who's really getting you to address that. Many thanks to the planning group shown here. We very much appreciate your efforts, and I think you'll see how effective they have been. Just a quick review of the agenda this morning, you'll hear about the state of the science and three sort of keynote talks, and then first sort of a first part of international experience. This includes a working lunch, and I'll say a little bit more about the lunch in a minute. In the afternoon, we go on to talk about case-binding, and then we have working groups, and the working groups have already done some work in advance, and we very much appreciate that. The next day then, we have a second part of international experience, some special topics, areas related to SJSTEN, but not specifically that. Again, we make you work during lunch, our apologies, and then report of the working groups and wrap up, and then we'll have a shuttle to take you back to either to the hotel or to nearby airports. As Eric mentioned, we have a video live stream. It's being broadcast live, so you may, and you might get caught on camera, so you just might want to be aware of that. There's a link available if you wanted to log on and see what's being shown. This is very important, please use the microphones, and one of the reasons for going around the table was to give everybody practice at turning it on, and also very importantly, turning it off, so if I could ask, Robert, thank you. Robert, if you could just turn your microphone off, Bob. Yeah, thanks, that's great. So that's the way that you know that it's there. At least I wasn't mumbling under my breath. And then we do have a hand mic for people who aren't at the table, so either come to the table, sort of work your way in, or raise your hand, and we'll bring a hand mic around to you. Yeah, we think it's a nice way to stimulate collaboration to actually have you come into the table and lean in. There is a floor mic, but it's way over at the end there, but it really is important that you use the microphones, and we'll be relentless about reminding you to do that, so let's see, food. So food is a very sore topic here, and we are really, really sorry. There are certain government regulations, we are a government agency, and we apologize, we are not allowed to pay for meals in any way, shape, or form. We can't even give you coffee. We can still give you water. That may, you know, by the end of today, it may disappear, so drink it now, but at any rate. So our sincere apologies, this is just the state of things. There is a cafeteria on the first floor, it's a little bit tricky to find, and so I might just ask, is anyone planning to buy lunch from the cafeteria? Just raise your hands, oh, you poor souls. Okay, so it is a nice cafeteria, finding it. So do you know how to get to it, Mark? Okay, so Mark Williams, in the Purple Sweater, will be the pioneer that will lead you down to take you down to the cafeteria. It's a little tricky to get out of, and then back up here, and we have a relatively short break for lunch, so we would encourage you to kind of grab what you can, come back up here, and we'll be able to sit at the tables here and eat, so it is a working lunch. Those of you who ordered lunch online, which was no small feat, the first time I went on to that website, it was really quite a challenge to navigate, but at any rate, it'll be delivered up here, and we'll eat here, and unfortunately the speaker during lunch will have to listen to our munching, and then we very much hope you can join us for the conference dinner tonight at Bistro Provence. Again, we apologize, we can't buy you dinner, so it's sort of a cash only, but please sign up at the registration table by the end of the first break if you're planning to come to the dinner, and there's a map in your packet for how to get there. So we have a registration desk out front, you probably met Jennifer and Josh from Capital Consulting, they will help with logistics questions, any problems logging into the guest network and taxi arrangements if you need them tomorrow. There's a shuttle to the hotel, I believe it's actually the B3 level, is that correct, yeah, so our apologies. This building is built on a hill and so every door is on a different floor, which gets increasingly confusing, but it's actually the B3 level if you go down to those elevators, and that will be leaving at six, we finish at 5.45, and then we'll pick you up again at 7.15 tomorrow, and just sincere thanks to the planning committee who did really a fabulous job, particularly I have to call out my colleagues, Carolyn Hutter and Deborah Cole and Tony, who did just the lion's share of the work here, it's really a fabulous job. And then we have a working group that helped us to identify the need for this conference and some of the people to bring in, and other institutes that are collaborating with us on this. So with that, it's my great pleasure to introduce co-chair, Neal Scheer from the University of Toronto, and he'll be giving the first keynote. Would you like the? Yeah, I'll just sit over there. Okay.